NASDAQ: CRDLCardiol Therapeutics Inc Stock
$0.97-0.04 (-3.96%)
Updated Apr 21, 2025
CRDL Price
$0.97
Fair Value Price
N/A
Market Cap
$80.13M
52 Week Low
$0.77
52 Week High
$3.12
P/E
-2.74x
P/B
4.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.29
Operating Cash Flow
-$17M
Beta
1.39
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CRDL Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses developing anti-fibrotic and anti-inflammatory therapies to treat cardiovascular disease. Its lead product is CardiolRx, which reduces cardiovascular and respiratory events in patients hospitalized with COVID-19. The company is also developing a subcutaneous formulation of CardiolRx to treat fibrosis and inflammation that progress to heart failure. Cardiol Therapeutics was incorporated in 2017 and is headquartered in Oakville, Ontario, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRDL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CRDL
Ranked#51 of 54
Ranked#51 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.13 | A | |
| $13.89 | A | |
| $30.29 | A |
Be the first to know about important CRDL news, forecast changes, insider trades & much more!
CRDL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRDL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRDL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRDL is poor value based on its book value relative to its share price (4.67x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.98x)
P/B vs Industry Valuation
CRDL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRDL due diligence checks available for Premium users.
Valuation
CRDL fair value
Fair Value of CRDL stock based on Discounted Cash Flow (DCF)
Price
$0.97
Fair Value
$0.38
Overvalued by
155.11%
CRDL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRDL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.74x
Industry
20.59x
Market
27.14x
CRDL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.67x
Industry
1.98x
CRDL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRDL's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.7M
Profit Margin
0%
CRDL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$22.1M
Liabilities
$5.0M
Debt to equity
0.29
CRDL's short-term assets ($21.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRDL's short-term assets ($21.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRDL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRDL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
-$4.3k
Financing
$13.0M
CRDL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRDL vs Pharmaceutical Stocks
Cardiol Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.